Bcl-2 Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Bcl-2 inhibitors, such as ABT-737, ABT-263, and ABT-199, while effective in treating certain cancers, face challenges like thrombocytopenia and tumor lysis syndrome, limiting their therapeutic window and efficacy.
Innovation Solution
Development of compounds represented by Formulas (I), (II), and (III), which are Bcl-2 inhibitors with specific structural features, aiming to provide improved pharmaceutical properties such as enhanced solubility, stability, bioavailability, and therapeutic index compared to existing Bcl-2 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Bcl-2 inhibitors (ABT-737, ABT-263, ABT-199) are used to treat cancers, then cancer cell apoptosis is enhanced, but severe side effects such as thrombocytopenia and tumor lysis syndrome occur
Solution Approach 1:
The patent applies local quality by designing Bcl-2 inhibitors with specific structural features (Formula I compounds with defined substituents R1-R6, Z1, W, and tricyclic core) that provide selective binding to Bcl-2 protein. This selectivity allows the drug to target cancer cells with Bcl-2 overexpression while sparing normal cells, thereby reducing thrombocytopenia and tumor lysis syndrome while maintaining anti-cancer efficacy.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the Bcl-2 inhibitor molecules, including substituent types (aryl, heteroaryl, cycloalkyl groups), positional arrangements (R1-R6 positions), and core structure modifications. These parameter changes optimize the drug's binding affinity and selectivity to achieve effective cancer treatment with reduced toxicity.
2Reliability
If Bcl-2 inhibitors are developed with improved pharmaceutical properties (solubility, stability, bioavailability), then therapeutic window is expanded, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the Bcl-2 inhibitor molecule into distinct functional segments: a core tricyclic structure ( Forms I, II, or III), substituent groups (R1-R6 at specific positions), and linkage moieties (Z1, W). This segmentation allows independent optimization of each segment's contribution to pharmaceutical properties while maintaining overall molecular manageability and reducing synthetic complexity.
Data Source
AI summary
The disclosure includes compounds of Formula (I)wherein W, R1, R2, R3, R4, R5, R6, m, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.